Benzinga

JANUARY 5, 2024

SomaLogic common stock and public warrants have ceased trading and will no longer be listed on the NASDAQ Global Select Market. The combined company is moving forward focused on: Expanding its commercial reach and maximizing cross-selling opportunities through complementary offerings and end markets.

Capital Structure 40

Capital Structure Technology Marketability 40

Benzinga

NOVEMBER 25, 2024

Based on current expected terms and conditions of the new non-recourse financing, the acquisition is expected to provide incremental annual levered asset CAFD on a five-year average basis of approximately $9 million beginning January 1, 2026. Clearway continues its successful track record of executing accretive, third-party acquisitions.

Dividends 49

Dividends Capital Structure EBITDA Finance 49

Benzinga

DECEMBER 21, 2023

We urge you to vote "FOR" the Merger on SomaLogic's proxy card for three key reasons: 1. The Merger delivers compelling long-term upside, positions SomaLogic for leadership in the current market and reduces risk. We expect this will deliver $300 million in combined revenue by 2026. To be clear, this transaction is not a sale.

Capital Structure 40

Capital Structure Dividends Equity Marketability 40

Benzinga

OCTOBER 4, 2023

Strategic and Financial Benefits Creates a multi-omic technology leader, targeting large, high growth markets with a diverse portfolio of life science tools that power industry-leading throughput and data quality. Expands commercial reach and maximizes cross-selling opportunities through complementary offerings and end markets.

Technology 40

Technology Capital Structure Equity Marketability 40